Acesso livre
Acesso livre

Covid-19 (Temas de Saúde Pública)

Estudo de coorte | Infecção por COVID-19 garantiu aos pacientes uma proteção forte e duradoura contra reinfecção.

25 Abr, 2022 | 12:25h

Comunicado de imprensa: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services

Estudo original: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open

Comentário: COVID-19 infection may offer similar immunity as vaccination – CIDRAP

 

Comentário no Twitter

 

Covid não revelou todos os seus segredos. Aqui estão 6 mistérios que os especialistas esperam desvendar.

21 Abr, 2022 | 12:30h

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel – STAT

Liberadas para estudo clínico as vacinas candidatas da Sinopharm e Sinovac específicas para variante Ômicron da COVID.

21 Abr, 2022 | 11:42h

Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial – Reuters

 

Comentário no Twitter

 

M-A | Prevalência global da condição pós-COVID-19 ou COVID longa.

21 Abr, 2022 | 11:37h

Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review – The Journal of Infectious Diseases

Comentário: Global data reveal half may have long COVID 4 months on – CIDRAP

 

Comentário no Twitter (fio – clique para saber mais)

 

Revisão sistemática da eficácia e da efetividade da vacina para COVID-19 contra infecção e doença pelo SARS-CoV-2.

21 Abr, 2022 | 11:35h

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease – Open Forum Infectious Diseases

 

Comentário no Twitter

 

Estudo de vigilância de anticorpos | Transmissão domiciliar do SARS-CoV-2 entre os contatos domiciliares de indivíduos assintomáticos não vacinados e os sintomáticos com infecção confirmada.

19 Abr, 2022 | 12:50h

Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study – CMAJ Open

Comentário: COVID-19 household transmission is high, with children being a significant source of spread: study – CHEO

 

Comentário no Twitter (fio – clique para saber mais)

 

Revisão | Covid-19: virologia, variantes e vacinas.

19 Abr, 2022 | 12:48h

Covid-19: virology, variants, and vaccines – BMJ Medicine

 

Comentário no Twitter

 

Análise observacional em Israel mostrou que a 4ª dose da vacina da Pfizer pode reduzir o risco de curto prazo dos desfechos adversos relacionados a Covid-19.

18 Abr, 2022 | 15:31h

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine

Editorial: Covid-19 Boosters — Where from Here?

Conteúdos relacionados:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Estudo mostrou baixas taxas de COVID-19 grave em crianças internadas com infecção por SARS-CoV-2 confirmada.

18 Abr, 2022 | 15:29h

Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England – Journal of Infection

Comentário: Severe COVID-19 extremely rare among children – News Medical

Conteúdos relacionados:

[Preprint] Risk of Hospitalization, severe disease, and mortality due to COVID-19 in children with SARS-CoV-2 infection in Germany – “overall hospitalization rate associated with SARS-CoV-2 infection was 35.9 per 10,000 children, ICU admission rate was 1.7 per 10,000 and case fatality was 0.09 per 10,000”.

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

COVID-19 disease severity in children infected with the Omicron variant.

Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year.

Study identifies risk factors for severe CoviD-19 in children.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

International study identifies predictors of severe outcomes in children with COVID-19.

Perspectiva | O conceito clássico de imunidade de rebanho pode não se aplicar à COVID-19.

14 Abr, 2022 | 17:46h

The Concept of Classical Herd Immunity May Not Apply to COVID-19 – The Journal of Infectious Diseases

Comunicado de imprensa: NIH experts discuss controlling COVID-19 in commentary on herd immunity – NIH News Releases

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.